Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03699293 · ClinicalTrials.gov registry record · Phase 4

NSAIDs vs. Coxibs in the Presence of Aspirin

A Phase 4 study of Cardiovascular Diseases and Rheumatoid Arthritis, sponsored by Inova Health Care Services.

Recruiting
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT03699293 is a Phase 4 study of Cardiovascular Diseases and Rheumatoid Arthritis that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 30 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03699293, a Phase 4 study of Cardiovascular Diseases and Rheumatoid Arthritis, is actively recruiting participants, sponsored by Inova Health Care Services.

RECRUITING
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial function.

Interventions

  • DRUG celecoxib 200mg capsule
  • DRUG naproxen sodium 550mg tablet
  • DRUG Aspirin 81mg tablet

Study Locations (1)

Virginia

  • Inova Heart and Vascular Institute - Falls Church

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-09-22
Est. Completion 2019-11-24
Phase Phase 4

Sponsor

Inova Health Care Services

75 total trials

What the Registry Record Tells You About NCT03699293

The ClinicalTrials.gov registry entry for NCT03699293 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 3 interventions - of which celecoxib 200mg capsule is the first listed.

NCT03699293 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT03699293 about?

NCT03699293 is a clinical study titled "NSAIDs vs. Coxibs in the Presence of Aspirin". The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial function.

What is the current status of trial NCT03699293?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2018-09-22. Estimated completion is 2019-11-24.

What conditions does trial NCT03699293 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Rheumatoid Arthritis.

What interventions are being tested in trial NCT03699293?

The interventions under investigation include: celecoxib 200mg capsule (DRUG), naproxen sodium 550mg tablet (DRUG), Aspirin 81mg tablet (DRUG).

Who is sponsoring clinical trial NCT03699293?

This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03699293 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.